Related by context. All words. (Click for frequent words.) 70 HBV 70 hepatitis C virus 69 hepatitis C virus HCV 68 HCV infection 66 HCV infected 65 chronic hepatitis C 64 antiviral therapy 64 HCV genotype 1 63 nucleotide analog 62 hepatitis C genotype 62 chronic HCV infection 62 peginterferon 62 HCV genotypes 62 Hepatitis C virus 62 celgosivir 62 mAb 61 hepatitis C HCV 61 antiviral activity 61 TMC# [001] 61 chronic hepatitis B 61 CCR5 tropic HIV 61 CCR5 antagonist 61 hepatitis C 61 Hepatitis C virus HCV 61 chronic HCV 60 NNRTIs 60 antiviral therapies 60 viral load 60 NNRTI 60 nucleoside 60 lupus nephritis 60 Hepatitis B virus 60 interferon 60 pegylated interferon 60 HCV genotype 60 nucleoside analogues 60 chronic hepatitis C. 60 bevirimat 60 mRCC 60 pomalidomide 60 valopicitabine 60 decitabine 59 PegIFN RBV 59 monoclonal 59 HCV infections 59 NS5b 59 latent tuberculosis infection 59 maribavir 59 relapsed multiple myeloma 59 OncoVEX GM CSF 59 bortezomib 59 HBsAg 59 chronic HBV infection 59 treatment naive genotype 59 nitazoxanide 59 BRAF mutation 59 Telaprevir 59 MAb 59 NRTI resistance 59 metastatic renal cell carcinoma 59 CMV 59 posaconazole 59 Amigal 59 HIV 59 sustained virological response 59 HBeAg negative 59 hepatitis B virus HBV 59 viral kinetics 58 seroconversion 58 hematological cancers 58 NSCLC 58 NS4A 58 VZV 58 Symadex 58 Gleevec resistant 58 HBV infection 58 HGS ETR1 58 latent TB infection 58 integrase inhibitor 58 telaprevir 58 ribavirin RBV 58 LTBI 58 T#I mutation 58 Boceprevir 58 Hepatitis C Virus HCV 58 adenoviral 58 dacetuzumab 58 metastatic RCC 58 HspE7 58 anti TNF 58 pegylated interferons 58 nucleoside analogue 58 CCR5 tropic 58 immunomodulator 58 virus HCV infection 58 HBV DNA 58 leukemia AML 58 polymerase inhibitor 58 treatment naïve genotype 58 oral antiviral 58 antibody 58 telbivudine 58 S. aureus 58 nucleotide analogs 58 HCV polymerase inhibitor 58 elotuzumab 58 multidrug resistant 58 SCCHN 58 Hepatitis C HCV 58 tipranavir 57 HCV viral 57 cilengitide 57 multiple myeloma MM 57 IMGN# 57 ganetespib 57 protease inhibitor 57 genotypic resistance 57 Cethromycin 57 INCB# [001] 57 bendamustine 57 Reverset 57 entecavir 57 pegylated interferon alpha 57 micafungin 57 oral prodrug 57 Telintra 57 hepatitis C infection 57 null responder 57 maraviroc 57 elvucitabine 57 virus HCV 57 chronic HBV 57 virologic failure 57 CMV disease 57 NY ESO 57 CD# antibody [001] 57 Hemopurifier 57 FLT3 57 CD8 responses 57 HIV coinfected 57 elvitegravir 57 PEG Interferon lambda 57 HIV infected 57 T#I [002] 57 log# reduction 57 ALN TTR 57 trabectedin 57 Virulizin ® 57 CLL 57 diabetic nephropathy 57 mapatumumab 57 SCH # 57 Ribavirin 57 lamivudine 57 pradefovir 57 castration resistant prostate cancer 57 daptomycin 57 BiovaxID 57 disease progression 57 CXCR4 57 peginterferon alfa 2a 57 INGN 57 AEGR 57 HBeAg positive 57 IDX# 57 AP# [003] 57 Hepatitis C 57 AEG# 57 Omacetaxine 57 seronegative 57 Actilon 57 BCR ABL inhibitors 57 antibody MAb 57 Blinatumomab 57 hepatocellular carcinoma 56 HIV RNA 56 XmAb# 56 delta isoform 56 Gag polymorphisms 56 CD# antibodies 56 G CSF 56 PSN# [002] 56 protease inhibitors 56 forodesine 56 trastuzumab 56 virological response 56 APTIVUS 56 panobinostat 56 interferon ribavirin 56 PXD# 56 heavily pretreated 56 Valortim R 56 XL# [003] 56 mAbs 56 perifosine 56 iclaprim 56 Viramidine 56 OHR/AVR# 56 S/GSK# 56 HAART 56 Chronic Hepatitis C 56 metastatic melanoma 56 sustained virologic response 56 IFN alpha 56 huN# DM1 56 IMC A# 56 HPV# 56 velafermin 56 HCV SPRINT 56 inhibitor RG# 56 Fludara 56 telaprevir VX 56 otelixizumab 56 Telbivudine 56 NRTI 56 bardoxolone 56 raltegravir 56 Velcade bortezomib 56 ceftazidime 56 CBLC# 56 Hepatitis C Virus 56 IGF 1R 56 EGFR inhibitors 56 DermaVir Patch 56 replicon 56 HuMax CD4 56 JAK3 56 enfuvirtide 56 ISENTRESS 56 VAX# 56 Elvitegravir 56 leukemia CLL 56 torezolid 56 TMC# [002] 56 TREANDA 56 Interferon alfa 56 refractory chronic myeloid 56 HBeAg negative patients 56 CCX# 56 humanized monoclonal antibody 56 gastrointestinal stromal tumors GIST 56 MAXY alpha 56 PRTX 56 peg IFN 56 Thiovir 56 CANCIDAS 56 rituximab 56 HCV RNA 55 JAK inhibitor 55 VIR# 55 Pegylated Interferon 55 disease modifying 55 Vacc 4x 55 Neisseria gonorrhoeae 55 Dapagliflozin 55 oritavancin 55 chronic myeloid leukemia CML 55 EpCAM 55 CCR5 receptor antagonist 55 therapeutic regimens 55 BCR ABL 55 HBeAg positive patients 55 HCV replicon 55 hepatitis C. 55 monoclonal antibody MAb 55 prostate cancer CaP 55 CCR5 inhibitor 55 caspofungin 55 erlotinib Tarceva ® 55 PRT# 55 S. aureus infections 55 Aurora kinase 55 BARACLUDE ® 55 EndoTAG TM -1 55 ocrelizumab 55 latent TB 55 Zolinza 55 Traficet EN 55 Virologic 55 receptor tyrosine kinase inhibitor 55 human immunodeficiency virus 55 Epratuzumab 55 Amplicor 55 tipranavir ritonavir 55 Debio 55 pharmacokinetic interactions 55 targeting CD# 55 multidrug resistance 55 antiviral 55 AmBisome 55 Tamibarotene 55 pegylated interferon alfa 55 refractory AML 55 NXL# 55 Sym# 55 chronic hepatitis B. 55 JVRS 55 dasatinib Sprycel ® 55 Pralatrexate 55 Nanobody 55 ribavirin 55 antibody responses 55 invasive aspergillosis 55 glufosfamide 55 refractory CLL 55 Insegia 55 HGS# 55 castrate resistant prostate cancer 55 apricitabine 55 anti CD3 55 Aptivus ® 55 nucleoside analog 55 daclizumab 55 H pylori 55 hepatocellular cancer 55 anti tubercular 55 Perifosine 55 Vicriviroc 55 tuberculin skin testing 55 immunomodulatory 55 tyrosine kinase inhibitor TKI 55 anticancer therapies 55 genotype 55 cell lymphomas 55 obatoclax 55 autoantibody 55 Factor VIIa 55 hematologic malignancies 55 talabostat 55 CLL SLL 55 Fabry Disease 55 viral subtypes 55 antiretroviral therapy 55 e antigen HBeAg 55 imatinib therapy 55 IFN α 55 Allovectin 7 R 55 Vitaxin 55 CYT# potent vascular disrupting 55 HIV HCV coinfected 55 alpha 2a 55 enzastaurin 55 pharmacologic intervention 55 interferon alpha 55 LHRH antagonists 55 tyrosine kinase inhibitor 55 epigenetic therapies 55 CD# monoclonal antibody 55 polymerase inhibitors 55 MGCD# [001] 55 HDACi 55 Elacytarabine 55 CYC# 55 solid tumors 55 OMAPRO 55 metastatic renal cell 55 IgM 55 combination antiretroviral therapy 55 interferon IFN 55 investigational protease inhibitor 55 Interferon alpha 55 huC# DM4 55 Altastaph 55 humanized antibody 55 JAK1 55 rilpivirine 55 Hepatitis B Virus 55 genotype 1b 55 antiviral efficacy 55 elacytarabine 55 belinostat 55 Alocrest 55 refractory gout 55 palifosfamide 55 pertuzumab 55 immunosuppressive regimens 55 molecularly targeted 55 non nucleoside HCV 55 serum HBV DNA 55 Staphylococcus aureus infections 55 FUZEON 55 Peg IFN 55 ribavirin therapy 55 effector function 55 achieve sustained virologic 55 XL# XL# 55 Oritavancin 55 RDEA# 55 null responder HCV 55 Cloretazine 55 protease inhibitor PI 54 Copegus ribavirin 54 vidofludimus 54 Civacir 54 Vidofludimus 54 EGFR tyrosine kinase inhibitors 54 TNFa 54 recurrent genital herpes 54 HRPC 54 Phase Ib II 54 cytomegalovirus 54 Rheumatoid Arthritis RA 54 axitinib 54 T2DM 54 virologic 54 Azixa 54 advanced NSCLC 54 relapsed AML 54 virus HBV 54 REYATAZ R 54 small molecule inhibitors 54 ritonavir boosted 54 OXi# 54 dasatinib Sprycel 54 AV HALT 54 HCV antibody 54 blinatumomab 54 LymphoStat B 54 GFT# 54 MAbs 54 MEK inhibitor 54 immunotherapeutic 54 AEZS 54 interferons 54 Carfilzomib 54 boosted protease inhibitor 54 neutralizing antibody 54 antisense drug 54 IRX 2 54 relapsed refractory 54 NNRTI resistance 54 chlorambucil 54 Antiviral Activity 54 virologic response 54 vicriviroc 54 investigational humanized monoclonal antibody 54 relapsed ovarian cancer 54 TBC# 54 Hemopurifier ® 54 Hepatitis B 54 YONDELIS 54 refractory multiple myeloma 54 indolent NHL 54 BAY #-# 54 RhuDex ® 54 OMP #M# 54 trastuzumab Herceptin ® 54 relapsed leukemia 54 panitumumab Vectibix 54 Doxil ® 54 maturation inhibitors 54 abiraterone acetate 54 humanized anti 54 CCR5 inhibitors 54 anti EGFR antibody 54 BCX# 54 neutralizing antibodies 54 BAL# [001] 54 noninfectious uveitis 54 darunavir 54 INCB# [002] 54 SEBIVO 54 kinase inhibitors 54 hepatitis B 54 T#I mutant 54 Tofacitinib 54 cancer immunotherapies 54 DAS# [001] 54 TYZEKA 54 B CLL 54 plus ribavirin 54 peginterferon ribavirin 54 personalized immunotherapy 54 imatinib 54 Herceptin trastuzumab 54 PEG IFN 54 REMUNE R 54 metastatic disease 54 HuLuc# 54 INT# [002] 54 adefovir 54 indinavir 54 IMC #B 54 immune modulators 54 PLX# 54 HQK 54 imatinib Gleevec 54 CEQ# 54 hepatitis B virus 54 solithromycin 54 VEGF receptor 54 ponatinib 54 FOLOTYN 54 Defibrotide 54 kinase inhibitor 54 Ozarelix 54 EOquin 54 HBV vaccine 54 volociximab 54 viremia 54 peripheral blood mononuclear 54 IgG1 antibody 54 ACZ# 54 delafloxacin 54 oral FTY# 54 nucleoside analogs 54 sapacitabine 54 histone deacetylase HDAC inhibitor 54 HIV1 54 tivozanib 54 antithrombotics 54 Daclizumab 54 systemic lupus erythematosus SLE 54 amphotericin B 54 Dacogen injection 54 liver metastases 54 viral replication 54 HGS ETR2 54 rhIL 7 54 TroVax ® 54 ON #.Na 54 albinterferon alfa 2b 54 fidaxomicin 54 interleukin IL -# 54 multiple myeloma 54 cell lymphoma CTCL 54 monoclonal antibody 54 ascending doses 54 AZT zidovudine Retrovir 54 sunitinib 54 canakinumab 54 Phase #/#a 54 CD# [002] 54 APTIVUS r 54 HCV protease inhibitors 54 CMV infection 54 docetaxel 54 recurrent glioma 54 NRTIs 54 HER2 overexpression 54 metastatic malignant melanoma 54 sJIA 54 Natalizumab 54 lumiliximab 54 Aflibercept 54 trastuzumab DM1 T DM1 54 XmAb ® 54 PEG interferon 54 genotype 1a 54 RSV 54 anti leukemic 54 lentiviral vector 54 preclinical 54 HPV-#/# 54 seropositive patients 54 fusion inhibitor 54 biologic therapy 54 relapsed refractory multiple myeloma 54 Chlamydia trachomatis 54 Valopicitabine 54 CD3 monoclonal antibody 54 Neulasta ® 54 Alferon N 54 Triolex 54 LY# [002] 54 HER2/neu 54 HIV integrase inhibitor 54 AVN# [001] 54 Mycobacterium tuberculosis 54 vinorelbine 54 chronic hepatitis 54 antithrombotic 54 sargramostim 54 seliciclib 54 idarubicin 54 KRAS mutant tumors 53 HCD# [002] 53 hepatocellular carcinoma HCC 53 genotypic 53 seropositive 53 CYT# 53 nelfinavir 53 vismodegib 53 anti TNF alpha 53 IgG 53 topoisomerase 53 HPV 53 MDR tuberculosis 53 ritonavir boosting 53 null responders 53 thrombopoietin 53 Tipranavir 53 Bcr Abl mutations 53 pegylated liposomal doxorubicin 53 bexarotene 53 ofatumumab 53 immunosuppressive therapies 53 chemotherapy induced neutropenia 53 dasatinib 53 pegylated interferon alfa 2a 53 eculizumab 53 ganciclovir 53 Ampligen R 53 cetuximab Erbitux R 53 Phase Ib clinical 53 NPM1 mutation 53 KRAS mutation 53 virologic suppression 53 HER2 antibody 53 Respiratory Syncytial Virus RSV 53 DLBCL 53 Exelixis XL# 53 sorafenib Nexavar 53 Talabostat 53 HBeAg seroconversion 53 HTLV 53 non nucleoside 53 Acute Myeloid Leukemia AML 53 antibody mediated 53 FOLOTYN ® 53 synthetic retinoid 53 chronic lymphocytic leukemia CLL 53 rilonacept 53 EGFr 53 Clevudine 53 Archexin 53 chlamydial infection 53 bosutinib 53 tigecycline 53 anti VEGF 53 metaglidasen 53 voreloxin 53 systemic lupus erythematosus 53 Sustained Virologic Response 53 imatinib Gleevec ® 53 mTOR inhibitors 53 selective modulator 53 Factor IX 53 predictive biomarkers 53 HER2 positive breast cancer 53 Azedra 53 MYDICAR ® 53 trastuzumab emtansine T DM1 53 Amrubicin 53 ovarian carcinoma 53 GvHD 53 M#V mutation 53 TLR9 agonist 53 trastuzumab Herceptin R 53 BCG refractory 53 CTLA 4 53 boceprevir 53 epratuzumab 53 SHPT 53 inhibit replication 53 Panzem R NCD 53 pDCs 53 gefitinib 53 oral protease inhibitor 53 nucleotide analogues 53 CsA 53 PEGylated 53 DMARD 53 calcineurin inhibitors 53 relapsed MM 53 pancreatic NET 53 Mipomersen 53 Myelodysplastic Syndrome MDS 53 antitumor 53 Arcalyst 53 CCR9 antagonist 53 lamivudine refractory patients 53 BARACLUDE R 53 Alinia 53 Restanza 53 TRIOLEX 53 Glufosfamide 53 imetelstat 53 DEB# 53 deforolimus 53 Targretin 53 prostate cancer CRPC 53 TMC# r 53 piperacillin tazobactam 53 ALN RSV# 53 HER2 positive metastatic breast 53 receptor monoclonal antibody 53 APOPTONE 53 Bezielle 53 generation NNRTI 53 coinfected 53 MDV# 53 vemurafenib 53 recurrent GBM 53 EGFR mutations 53 HCV Genotype 53 PARP inhibitors 53 K ras mutations 53 EZN 53 hematological malignancy 53 proteasome inhibitor 53 LY# [003] 53 anticancer therapy 53 Diamyd ® 53 protein kinase inhibitor 53 bone metastases 53 ATL/TV# 53 pegfilgrastim 53 TORISEL 53 severe sepsis 53 invasive candidiasis 53 PSMA ADC 53 peginterferon alfa 2b 53 interferon alfa 53 K ras 53 Apaziquone 53 HCV protease inhibitor 53 refractory NSCLC 53 virotherapy 53 CCR5 antagonists 53 surface antigen HBsAg 53 Tavocept 53 zanolimumab 53 PROSTVAC VF 53 TRO# 53 Ceflatonin R 53 elesclomol 53 telaprevir dosed 53 MEK inhibitors 53 AKT inhibitor 53 cangrelor 53 amrubicin 53 Pradefovir 53 virus HCV protease inhibitor 53 nonvaccine 53 viral suppression 53 JAK inhibitors 53 pafuramidine 53 milatuzumab 53 UGT#A# 53 Lenocta 53 EGFR antibodies 53 CTAP# Capsules 53 BRAF V# mutation 53 Myocet 53 antigen 53 Infected Patients 53 GeoVax vaccine 53 follicular lymphoma 53 cMET 53 Nitazoxanide 53 invasive fungal infections 53 Valortim ® 53 R5 tropic 53 CLORETAZINE TM VNP#M 53 Virulizin R 53 coinfected patients 53 BRIM3 53 ANA# 53 tipifarnib 53 Acute Radiation Syndrome ARS 53 Pegasys ® 53 Enzastaurin 53 siRNA 53 CHOP chemotherapy 53 HuMax CD# 53 Azilect ® 53 Arranon 53 CR# vcMMAE 53 pralatrexate 53 liver fibrosis 53 talactoferrin 53 RGB # 53 Phenoptin 53 Therapeutic Vaccine 53 HCV antiviral 53 DOS# 53 Beta catenin pathway 53 Dalbavancin 53 virological failure 53 LB# [003] 53 mycophenolate mofetil 53 rituximab Rituxan 53 evaluating tivozanib 53 Protease Inhibitors 53 sodium glucose cotransporter 53 Aplidin 53 immunomodulatory therapy 53 tanespimycin 53 systemic fungal infections 53 HIV infection 53 gemcitabine carboplatin 53 chronic HCV genotype 53 K#R [002] 53 CDAD 53 CIMZIA ™ 53 bone metastasis 53 erlotinib 53 alvespimycin 53 ARIKACE 53 therapeutic monoclonal antibodies 53 ozarelix 53 CCR5 mAb 53 imipenem 53 ISF# 53 Cytolin ® 53 Taxotere ® 53 ketolide antibiotic 53 nanoviricide 53 peptide antigens 53 serum HCV RNA 53 PKC# 53 depsipeptide 53 Recombinant interferon alpha 53 Entry Inhibitor 53 GRN#L 53 sunitinib malate 53 Raltegravir 53 dyslipidemia 53 Rituximab 53 infliximab 53 achieve sustained virological 53 DU #b 53 voriconazole 53 HAART regimens 53 Gleevec imatinib mesylate 53 antibody titer 53 Phase 1b 53 medullary thyroid cancer 53 preclinically 53 INTELENCE 53 Quinamed 53 VQD 53 Trastuzumab 53 Peginterferon 53 Epidermal Growth Factor Receptor 53 Allovectin 7 53 LEUKINE 53 radezolid 53 cytotoxic 53 ELISPOT 53 azacitidine 53 chemotherapeutic agents 53 tocilizumab 53 JAK2 V#F 53 recurrent glioblastoma multiforme 53 terlipressin 53 nosocomial pneumonia 53 STELARA 53 FluCide 53 cytomegalovirus CMV 53 Maribavir 53 HCV RESPOND 2 53 S. pneumoniae 53 interferon lambda 52 Golimumab 52 Irinotecan 52 recurrent ovarian cancer 52 ipilimumab 52 xenograft models 52 Stimuvax R 52 NS5A 52 superinfection 52 alkylating agent 52 IFN gamma 52 gastrointestinal stromal tumors 52 adecatumumab 52 induce apoptosis 52 rituximab refractory 52 DXL# 52 MyVax R 52 REYATAZ ® 52 Dr. McHutchison 52 CLL cells 52 lamivudine resistant 52 PTP 1B 52 thymalfasin 52 virologic responses 52 PROCHYMAL 52 LEXIVA r 52 CanAg 52 Tobira Therapeutics 52 Pharmacokinetics PK 52 hepatitis B infection 52 VEGF receptor inhibitor 52 prophylactic vaccines 52 oral JAK1 52 Pazopanib 52 MKC# MT 52 monoclonal antibody mAb 52 MAGE A3 52 ORENCIA ® 52 Telatinib 52 Pegasys plus Copegus 52 antidiabetic 52 budesonide foam 52 rhGH 52 PNP inhibitor 52 viral loads 52 PEG INTRON 52 Tarvacin 52 CaP 52 nilotinib 52 superficial bladder cancer 52 Japanese Encephalitis vaccine 52 atazanavir sulfate 52 subcutaneous formulation 52 TNFα 52 leukemia ALL 52 JAK2 inhibitor 52 nutlin 3a 52 pegylated 52 ISTODAX 52 rFIXFc 52 galiximab 52 pneumococcal serotypes 52 herpes simplex virus 52 ErbB2 positive 52 alfa 2a 52 hepatoma 52 metastatic neuroendocrine tumors 52 cell malignancies 52 INC# 52 TKI therapy 52 gefitinib Iressa 52 Onconase 52 adalimumab 52 BiTE antibody 52 Radezolid 52 HDAC 52 epithelial tumors 52 tumor necrosis 52 pan HDAC inhibitor 52 FVIIa 52 BENLYSTA TM 52 EGFRvIII 52 PREZISTA rtv 52 TransVax TM 52 VICTRELIS 52 ITMN 52 MGCD# [002] 52 dosing cohorts 52 interferon beta 52 CIMZIA TM 52 Phase Ib study 52 follicular lymphomas 52 LymphoStat B TM 52 4CMenB 52 antitumor activity 52 Janus kinase 52 Vectibix 52 darunavir Prezista 52 carfilzomib 52 ara C 52 Peg Intron 52 HCV polymerase inhibitors 52 atacicept 52 MAXY G# 52 potent antiretroviral therapy 52 Imprime PGG 52 SAR# [004] 52 protease inhibitor telaprevir 52 Akt inhibitor 52 antiangiogenesis 52 teduglutide 52 MT# MEDI 52 pharmacodynamic PD 52 ChronVac C ® 52 MYDICAR 52 cariprazine 52 StaphVAX 52 p# biomarker 52 microbiological eradication 52 Homspera 52 MyVax 52 interferon therapy 52 GM CSF 52 UPLYSO 52 Sapacitabine 52 naive HCV 52 survivin 52 Annamycin 52 Tarceva erlotinib 52 Hepsera 52 LUX Lung 52 HoFH 52 Imatinib 52 antibodies 52 anti fibrotic 52 SUTENT 52 BEXXAR 52 administered subcutaneously 52 cART 52 Bortezomib 52 mertansine 52 TG# [001] 52 relapsed SCLC 52 AMPK activators 52 lymphoid malignancies